Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease

Archive ouverte

Macek Jilkova, Zuzana | Hilleret, Marie Noelle | Gerster, Theophile | Sturm, Nathalie | Mercey-Ressejac, Marion | Zarski, Jean-Pierre | Leroy, Vincent | Marche, Patrice | Costentin, Charlotte | Decaens, Thomas

Edité par CCSD ; MDPI -

International audience. Immune checkpoint molecules (ICM) are critical in maintaining immunologic homeostasis and participate in preventing or promoting autoimmune disease development. Exploring a large panel of intrahepatic inhibitory and stimulatory ICM is necessary for drawing a general picture of the immune alterations in autoimmune hepatitis (AIH). Here, we performed a multiparametric analysis of ICM, including PD-1, TIM3, LAG3, CTLA-4, OX40 and 4-1BB, and we determined their expression on intrahepatic lymphocyte subsets in untreated and in treated patients with AIH in comparison to normal liver tissue. AIH patient-derived liver tissue revealed the overexpression of ICM, mainly PD-1 and 4-1BB, as well as the strong correlation between PD-1+ CD8+ T-cell abundance and severity of AIH (alanine transaminase and aspartate transaminase levels). Our results show that the ICM play an important role in the loss of immune homeostasis in the liver, providing an attractive approach to investigate their role as targets for effective therapeutic interventions.

Consulter en ligne

Suggestions

Du même auteur

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?

Archive ouverte | Macek Jilkova, Zuzana | CCSD

International audience

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges

Archive ouverte | Macek Jilkova, Zuzana | CCSD

International audience. Immunotherapies targeting immune checkpoints are fast-developing therapeutic approaches adopted for several tumor types that trigger unprecedented rates of durable clinical responses. Immune ...

Immunomodulation for hepatocellular carcinoma therapy: current challenges

Archive ouverte | Macek Jilkova, Zuzana | CCSD

International audience. Purpose of review The emergence of novel immunotherapies, such as immune-checkpoint inhibitors has changed the landscape of systemic cancer treatment. In hepatocellular carcinoma (HCC) patien...

Chargement des enrichissements...